144 related articles for article (PubMed ID: 529054)
21. Induction of peroxisome proliferation in rainbow trout exposed to ciprofibrate.
Yang JH; Kostecki PT; Calabrese EJ; Baldwin LA
Toxicol Appl Pharmacol; 1990 Jul; 104(3):476-82. PubMed ID: 2385837
[TBL] [Abstract][Full Text] [Related]
22. Single and chronic administration of ciprofibrate or of ciprofibrate-glycinate in male Fischer 344 rats: comparison of the effects on morphological and biochemical parameters in liver and blood.
Lupp A; Karge E; Danz M; Deufel T; Oelschläger H; Klinger W
Eur J Drug Metab Pharmacokinet; 2005; 30(3):203-18. PubMed ID: 16250258
[TBL] [Abstract][Full Text] [Related]
23. Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats.
Petit D; Bonnefis MT; Rey C; Infante R
Atherosclerosis; 1988 Dec; 74(3):215-25. PubMed ID: 3240333
[TBL] [Abstract][Full Text] [Related]
24. Induction of peroxisome proliferation and hepatic tumours in C57BL/6N mice by ciprofibrate, a hypolipidaemic compound.
Rao MS; Dwivedi RS; Subbarao V; Reddy JK
Br J Cancer; 1988 Jul; 58(1):46-51. PubMed ID: 2901849
[TBL] [Abstract][Full Text] [Related]
25. Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.
Lupp A; Karge E; Deufel T; Oelschlägers H; Fleck C
Arzneimittelforschung; 2008; 58(5):225-41. PubMed ID: 18589557
[TBL] [Abstract][Full Text] [Related]
26. The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.
Ferry N; Bernard N; Pozet N; Gardes E; Cuisinaud G; Labeeuw M; Zech PY; Sassard J
Br J Clin Pharmacol; 1989 Dec; 28(6):675-81. PubMed ID: 2611089
[TBL] [Abstract][Full Text] [Related]
27. Fatty acid metabolism in hepatocytes cultured with hypolipidaemic drugs. Role of carnitine.
Gerondaes P; Alberti KG; Agius L
Biochem J; 1988 Jul; 253(1):161-7. PubMed ID: 3048253
[TBL] [Abstract][Full Text] [Related]
28. [A clofibric acid derivative with hypolipemic and platelet antiaggregant action].
Dănilă G; Nechifor M; Filip M; Păduraru I; Ifrim C; Grădinariu D; Papa V; Manolescu A; Bădescu A
Rev Med Chir Soc Med Nat Iasi; 1988; 92(1):127-32. PubMed ID: 3393745
[No Abstract] [Full Text] [Related]
29. Ciprofibrate in the therapy of type II hypercholesterolemia. A double-blind trial.
Illingworth DR; Olsen GD; Cook SF; Sexton GJ; Wendel HA; Connor WE
Atherosclerosis; 1982 Aug; 44(2):211-21. PubMed ID: 6753860
[TBL] [Abstract][Full Text] [Related]
30. Differential proto-oncogene mRNA induction from rats treated with peroxisome proliferators.
Cherkaoui Malki M; Lone YC; Corral-Debrinski M; Latruffe N
Biochem Biophys Res Commun; 1990 Dec; 173(3):855-61. PubMed ID: 2268348
[TBL] [Abstract][Full Text] [Related]
31. [Hypolipidemic activity of glycine and its derivatives].
Ryzhenkov VE; Molokovskiĭ DS; Ioffe DV
Vopr Med Khim; 1984; 30(2):78-80. PubMed ID: 6740998
[TBL] [Abstract][Full Text] [Related]
32. Experimental pharmacological study of moroxybrate, a hypolipidaemic, antithrombotic, antiatheromatous agent.
Moreau P; Jacotot B; Tillement JP
J Pharm Pharmacol; 1987 Jan; 39(1):35-8. PubMed ID: 2880981
[TBL] [Abstract][Full Text] [Related]
33. Novel lipid-lowering properties of Vaccinium myrtillus L. leaves, a traditional antidiabetic treatment, in several models of rat dyslipidaemia: a comparison with ciprofibrate.
Cignarella A; Nastasi M; Cavalli E; Puglisi L
Thromb Res; 1996 Dec; 84(5):311-22. PubMed ID: 8948058
[TBL] [Abstract][Full Text] [Related]
34. Studies with etofibrate in the rat. Part I: Effects on glycerol, free fatty acid and triacylglycerol metabolism.
Herrera E; Lasunción MA; Castro M; Gómez-Coronado D; Martín A; Quack G
Biochim Biophys Acta; 1988 Nov; 963(1):42-52. PubMed ID: 3179329
[TBL] [Abstract][Full Text] [Related]
35. The short- and long-term effects of bezafibrate in the rat.
Fahimi HD; Reinicke A; Sujatta M; Yokota S; Ozel M; Hartig F; Stegmeier K
Ann N Y Acad Sci; 1982; 386():111-35. PubMed ID: 6953842
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the hepatic responses to the short-term administration of ciprofibrate in several rat strain. Co-induction of microsomal cytochrome P-450 IVA1 and peroxisome proliferation.
Makowska JM; Anders C; Goldfarb PS; Bonner F; Gibson GG
Biochem Pharmacol; 1990 Sep; 40(5):1083-93. PubMed ID: 2390105
[TBL] [Abstract][Full Text] [Related]
37. Effects of clofibric acid and bezafibrate administration on activities of alkaline phosphatase and other enzymes in livers of rats.
Walli AK; Seidel D
Res Exp Med (Berl); 1981; 179(2):153-61. PubMed ID: 7280363
[TBL] [Abstract][Full Text] [Related]
38. Dissociation of hypolipidemic and antiplatelet actions from adverse myotonic effects of clofibric acid related enantiomers.
Feller DR; Kamanna VS; Newman HA; Romstedt KJ; Witiak DT; Bettoni G; Bryant SH; Conte-Camerino D; Loiodice F; Tortorella V
J Med Chem; 1987 Aug; 30(8):1265-7. PubMed ID: 2441050
[TBL] [Abstract][Full Text] [Related]
39. The effect of three hypolipidemic drugs on catalase activity and peroxisomal and mitochondrial palmitate oxidation in rat cardiac and skeletal muscle.
MacDonald RS; Swan PB
Biochim Biophys Acta; 1986 Feb; 880(2-3):153-60. PubMed ID: 3942787
[TBL] [Abstract][Full Text] [Related]
40. Determination of ciprofibrate in human plasma by high-performance liquid chromatography.
Park GB; Biddlecome CE; Koblantz C; Edelson J
J Chromatogr; 1982 Feb; 227(2):534-9. PubMed ID: 7061664
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
